Aurobindo Pharma has received 7 observations from the United States Food and Drug Administration (USFDA) for its unit-7 in Telangana. The USFDA had conducted a Current Good Manufacturing Practices (CGMP) inspection at the company’s unit-7 manufacturing facility from September 19 to 27. The company is confident of addressing these issues within the stipulated timeline.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.